HIV/AIDS HAART: Nevirapine-containing HAART safe and effective long-term in drug-naïve HIV/AIDS patients

AIDSWEEKLY Plus; Monday, November 6, 2006
Staff Medical Writers

According to a recent study from France, "Data on the durability of antiretroviral regimens over a 3-year period have only rarely been reported. The aim of this study was to evaluate the long-term efficacy and safety of one or two daily doses of nevirapine (NVP), in combination with stavudine (d4T) and didanosine (ddI), in HIV-infected patients.

"This study was a follow-up of the VIR (amune) Grand Ouest (VIRGO) study, a 12-month open-label trial to assess the safety and immunovirological activity of NVP-d4T-ddI combination therapy in antiretroviral-naïve HIV-1-infected adults with baseline CD4 counts greater than or equal to200 cells/mcL and plasma viral loads greater than or equal to5000 HIV-1 RNA copies/mL."

"Of the 100 patients included in the study," reported the authors, "the 67 patients remaining on the initial triple therapy at the end of the study (1 year) were offered an extra 24 months of follow-up. Of the 60 patients who extended follow-up, 46 were still being treated with d4T-ddI-NVP at month 36; 91% (39/43) had a plasma viral load <500 copies/mL (data were missing for three patients)."

"CD4 cell counts increased over 36 months. Safety and tolerance were good with no unexpected long-term toxicity. After 3 years of treatment with NVP-d4T-ddI, nearly half of the patients were still receiving the initial antiretroviral therapy with a sustained and durable immunovirological benefit," wrote V. Reliquet and colleagues at Hospital Hotel Dieu in Nantes.

Investigators concluded, Long-term toxicity was mainly related to the nucleoside reverse transcriptase inhibitor components of the regimen."

Reliquet and colleagues published their study in HIV Medicine (Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naïve HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Med. 2006 Oct;7(7):431-6).

For additional information, contact V. Reliquet, Hopital Hotel Dieu, Service Malad Infection & Trop, 7eme Ouest, Pl Alexis Ricordeau, F-44093 Nantes 01, France.

Publisher contact information for the journal HIV Medicine is: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: Nantes, France, HIV/AIDS, Long Term Efficacy, Nevirapine, Viral Load, Long-Term Toxicity.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Reliquet V, Allavena C, Francois-Brunet C, et al., “Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study”, HIV Med. 2006 Oct;7(7):431-6.

PubMED Related articles Search

2006-11-06
AW061103

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.